Acadia Pharmaceuticals | ACAD - Sales Revenues


Acadia Pharmaceuticals reported $268.06M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
Acadia Pharmaceuticals USD 268.06M 15.94M Mar/2026
ALKERMES USD 392.91M 8.41M Mar/2026
Alnylam Pharmaceuticals USD 1.17B 70M Mar/2026
Biogen USD 2.25B 30M Mar/2026
BioMarin Pharmaceutical USD 766M 109M Mar/2026
Bristol-Myers Squibb USD 11.49B 1.01B Mar/2026
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Corcept Therapeutics USD 164.9M 37.22M Mar/2026
Cytokinetics USD 19.35M 1.59M Mar/2026
Eisai JPY 205.43B 14.51B Mar/2026
Eli Lilly USD 19.8B 500M Mar/2026
Incyte USD 1.27B 240M Mar/2026
J&J USD 24.1B 500M Mar/2026
Moderna USD 389M 289M Mar/2026
Neurocrine Biosciences USD 811M 5.5M Mar/2026
Pfizer USD 14.5B 3.08B Mar/2026
Prothena USD 51.08M 51.06M Mar/2026
PTC Therapeutics USD 273M 108.3M Mar/2026
Sarepta Therapeutics USD 730.8M 287.9M Mar/2026
Ultragenyx Pharmaceutical USD 136M 71M Mar/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024
Vertex Pharmaceuticals USD 2.99B 200M Mar/2026